	US 11,938,165 B2
	Stable pharmaceutical foam
Tamar Auerbach-Nevo, Rehovot (IL); Ashley Deanglis, Skillman, NJ (US); and Israel Nur, Nes Ziona (IL)
Assigned to Omrix Biopharmaceuticals Ltd., Kiryat-Ono (IL); and Ethicon, Inc., Raritan, NJ (US)
Filed by Omrix Biopharmaceuticals Ltd., Rehovot (IL); and Ethicon, Inc, Somerville, NJ (US)
Filed on Aug. 18, 2021, as Appl. No. 17/405,491.
Application 17/405,491 is a division of application No. 15/700,655, filed on Sep. 11, 2017, granted, now 11,123,397.
Claims priority of provisional application 62/394,371, filed on Sep. 14, 2016.
Claims priority of application No. 247810 (IL), filed on Sep. 14, 2016.
Prior Publication US 2021/0379140 A1, Dec. 9, 2021
Int. Cl. A61K 38/01 (2006.01); A61K 9/12 (2006.01); A61K 38/36 (2006.01); A61K 38/48 (2006.01); A61L 24/00 (2006.01); A61L 24/10 (2006.01); A61L 26/00 (2006.01)

CPC A61K 38/018 (2013.01) [A61K 9/122 (2013.01); A61K 38/014 (2013.01); A61K 38/363 (2013.01); A61K 38/4833 (2013.01); A61L 24/0036 (2013.01); A61L 24/10 (2013.01); A61L 26/0028 (2013.01); A61L 26/0085 (2013.01); C12Y 304/21005 (2013.01); A61L 2400/04 (2013.01)]

1 Claim

1. A method for preparing a pharmaceutical foam composition, comprising a step of: foaming a solution of a peptone with a gas,

(i) the solution of the peptone prepared by enzymatic hydrolysis of a full-length protein in an aqueous solution,

(ii) wherein said solution of the peptone is free of said full-length protein,

(iii) wherein the peptone is present at a concentration of at least 5% to less than about 50% w/v of the solution:

and wherein the method further comprises adding fibrinogen to said solution of said peptone, prior to said foaming.